Thomas M. Habermann

Thomas M. Habermann, M.D., is a distinguished Professor of Medicine at Mayo Clinic College of Medicine and Science in Rochester, Minnesota, where he specializes in Hematology within the Mayo Clinic Comprehensive Cancer Center. With over three decades of experience, Dr. Habermann has established himself as a leading expert in lymphoma research and treatment, particularly in B-cell lymphomas, hairy cell leukemia, and post-transplant lymphoproliferative disorders.

Dr. Habermann completed his medical training at Creighton University, earning both his undergraduate degree in Biology (1975) and his MD (1979), followed by residency and fellowship training at Mayo Clinic. He is board certified in Internal Medicine and Hematology and holds a master's faculty privilege in Clinical and Translational Science.

His research interests focus on malignant lymphomas, with significant contributions to understanding lymphoma classification, prognostic factors, and treatment outcomes. Analysis of his extensive publication record reveals a strong emphasis on translating molecular findings into clinical practice, particularly regarding lymphoma subtypes and their therapeutic implications.

• Henry S. Plummer Distinguished Physician Award
• 2012 Lifetime Achievement for Outstanding Contributions to Medical Education Award
• Mayo Clinic Distinguished Educator Award
• Multiple Teacher of the Year awards from the Mayo Fellows Association
• Minnesota Hope Award from the Lymphoma Research Foundation

As an educator, Dr. Habermann has held numerous leadership positions including education program director, head of section, associate chair of education in the Division of Hematology, and associate dean of internal medicine and medical subspecialties. His commitment to medical education has been recognized through multiple teaching awards throughout his career. He remains an active contributor to the field through his ongoing research, clinical practice, and participation in major professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and Lymphoma Research Foundation.